Mutual of America Capital Management LLC Purchases 1,926 Shares of Krystal Biotech, Inc. $KRYS

Mutual of America Capital Management LLC lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,357 shares of the company’s stock after purchasing an additional 1,926 shares during the period. Mutual of America Capital Management LLC owned 0.13% of Krystal Biotech worth $5,273,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after purchasing an additional 365,304 shares during the period. Braidwell LP increased its stake in shares of Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company’s stock worth $72,254,000 after purchasing an additional 200,244 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Krystal Biotech by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock worth $45,168,000 after purchasing an additional 7,344 shares during the period. Nuveen LLC bought a new position in shares of Krystal Biotech during the first quarter worth approximately $42,223,000. Finally, Woodline Partners LP increased its stake in shares of Krystal Biotech by 0.4% during the first quarter. Woodline Partners LP now owns 222,043 shares of the company’s stock worth $40,034,000 after purchasing an additional 941 shares during the period. Institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Bank of America raised their price objective on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Citigroup restated a “neutral” rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Finally, Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $223.00.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $190.78 on Wednesday. The stock’s fifty day moving average price is $162.81 and its two-hundred day moving average price is $151.55. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The firm has a market cap of $5.52 billion, a PE ratio of 38.78 and a beta of 0.64.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).